Earnings summaries and quarterly performance for Elanco Animal Health.
Executive leadership at Elanco Animal Health.
Jeffrey Simmons
Detailed
Chief Executive Officer
CEO
David Kinard
Detailed
Executive Vice President, Human Resources, Corporate Communications and Administration
Ellen de Brabander
Detailed
Executive Vice President, Innovation and Regulatory Affairs
Grace McArdle
Detailed
Executive Vice President, Manufacturing and Quality
James Meer
Detailed
Senior Vice President, Chief Accounting Officer
José Manuel Correia de Simas
Detailed
Executive Vice President, U.S. Farm Animal Business
Rajeev Modi
Detailed
Executive Vice President, U.S. Pet Health and Global Digital Transformation
Ramiro Cabral
Detailed
Executive Vice President and President, Elanco International
Robert VanHimbergen
Detailed
Chief Financial Officer
Shiv O'Neill
Detailed
Executive Vice President, General Counsel and Corporate Secretary
Timothy Bettington
Detailed
Executive Vice President, Corporate Strategy and Market Development
Board of directors at Elanco Animal Health.
Art Garcia
Detailed
Director
Deborah Kochevar
Detailed
Director
Denise Scots-Knight
Detailed
Director
Kapila Anand
Detailed
Director
Kirk McDonald
Detailed
Director
Lawrence Kurzius
Detailed
Chairman of the Board
Michael Harrington
Detailed
Director
Paul Herendeen
Detailed
Director
R. David Hoover
Detailed
Director
Stacey Ma
Detailed
Director
Research analysts who have asked questions during Elanco Animal Health earnings calls.
Michael Ryskin
Bank of America Merrill Lynch
6 questions for ELAN
Also covers: A, ALGN, AVTR +28 more
Brandon Vazquez
William Blair & Company, L.L.C.
4 questions for ELAN
Also covers: ALGN, CBLL, CVRX +16 more
Daniel Clark
Leerink Partners
4 questions for ELAN
Also covers: CERT, IDXX, IQV +3 more
Erin Wright
Morgan Stanley
4 questions for ELAN
Also covers: ALGN, BTSG, CAH +18 more
Jonathan Block
Stifel Financial Corp.
4 questions for ELAN
Also covers: ALGN, COO, CUTR +11 more
Andrea Zayco Narvaez Alfonso
UBS
3 questions for ELAN
Also covers: EVH, LFST, ZTS
Michael DiFiore
Evercore ISI
3 questions for ELAN
Also covers: AMGN, AMLX, BIIB +8 more
Navann Ty
BNP Paribas S.A.
3 questions for ELAN
Also covers: COO, EOLS, HOLX +4 more
Andrea Alfonso
UBS
2 questions for ELAN
Also covers: ZTS
Andrew Dusing
Cleveland Research
2 questions for ELAN
Balaji Prasad
Barclays
2 questions for ELAN
Also covers: ALVO, AMRX, LGND +7 more
Christopher Schott
JPMorgan Chase & Co.
2 questions for ELAN
Also covers: ABBV, AMGN, AMRX +15 more
David Westenberg
Piper Sandler
2 questions for ELAN
Also covers: ADPT, AKYA, CTKB +12 more
Ekaterina Pirogova
JPMorgan Chase & Co.
2 questions for ELAN
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for ELAN
Also covers: COO, DXCM, NYXH +1 more
Linda Bolduc
Morgan Stanley
2 questions for ELAN
Also covers: BTSG, PAHC
Navann Ty Dietschi
BNP Paribas
2 questions for ELAN
Also covers: COO, EOLS, GEHC +6 more
Umer Raffat
Evercore ISI
2 questions for ELAN
Also covers: ALKS, AMGN, BHC +15 more
Ekaterina Knyazkova
Cantor Fitzgerald
1 question for ELAN
Also covers: AMPH, ANIP, PAHC
Mike Curry
Evercore ISI
1 question for ELAN
Also covers: CAPC
Ross Sparenblek
William Blair & Company
1 question for ELAN
Also covers: EPAC, JBT, KAI +7 more
Recent press releases and 8-K filings for ELAN.
Elanco Discusses Margin Expansion, Deleveraging, and Product Growth at Healthcare Conference
ELAN
Guidance Update
Product Launch
New Projects/Investments
- Elanco is implementing "Elanco Ascend," a company-wide initiative aimed at growing EBITDA in 2026 through cost measures, automation, and investing in R&D and marketing.
- The company expects to achieve below three times leverage in 2027, having reduced debt from 5.6 times (2020-2023) to an anticipated 3.7-3.8 times by the end of the current year.
- Key innovation products like Zenrelia and Quattro are driving growth, with Zenrelia sales doubling from Q2 to Q3 and achieving nearly 45% clinic penetration in the US. The IL-31 product is expected to launch in the first half of next year.
- The farm animal business, which constitutes half of Elanco's operations, is highlighted for its stability and profitability, with EBITDA margins comparable to the pet health segment.
2 days ago
Elanco Discusses Margin Expansion, Product Innovation, and Deleveraging Strategy
ELAN
Guidance Update
New Projects/Investments
Product Launch
- Elanco is focused on gross margin expansion driven by its innovation basket and the Elanco Ascend initiative, which is expected to contribute to EBITDA growth in 2026 through cost measures, automation, and AI.
- The U.S. pet health business is experiencing significant growth due to innovation, with Zenrelia sales doubling from Q2 to Q3 and achieving 45% clinic penetration, while Quattro continues to perform well beyond expectations.
- The farm animal business is noted for its stability and profitability, with EBITDA margins on par with the pet side, and key products like Experior and Bovaer are expected to drive continued growth.
- Elanco anticipates reducing its debt leverage ratio to below three times in 2027, supported by strong free cash flow conversion and a recent refinancing that extended maturities.
- The company expects IL-31 approval to be imminent (potentially Q4) with a first-half launch next year, aiming to capture market share in the dermatology monoclonal antibody space.
2 days ago
Elanco Outlines Growth Drivers and Deleveraging Targets
ELAN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Elanco is implementing the Elanco Ascend initiative, a company-wide program focused on cost-related items, productivity measures, automation, and AI, aiming to improve gross margins and grow EBITDA in 2026.
- The company expects its innovation basket, including Quattro, Zenrelia, and Experior, to drive growth, with IL-31 anticipated for a first-half launch next year.
- Elanco aims to reduce its debt to below 3 times by 2027, supported by successful refinancing of its 2027 tower and strong free cash flow conversion.
- The farm animal business, which accounts for half of Elanco's operations, is highlighted for its stability and profitability, with EBITDA margins on par with the pet side, helping to mitigate macro challenges in vet visits.
- Zenrelia has demonstrated strong momentum, with total sales doubling from Q2 to Q3 and clinic penetration reaching close to 45% in the U.S., alongside rapid globalization with approvals in 36 OUS countries.
2 days ago
Elanco Discusses Growth, Innovation, and Debt Reduction at Conference
ELAN
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Elanco has achieved nine quarters of growth and possesses a basket of six approved innovative products, with a seventh (IL-31) expected.
- The company's innovation basket revenue guidance has been raised four times, with the midpoint now around $860 million, up from an initial $600 million-$700 million.
- Elanco is focused on reducing its debt leverage from 3.7 times to low threes, high twos as soon as possible, which is the number one use of cash.
- A five-year productivity initiative called Elanco Ascend has been launched to improve margins and cash flow across various operations.
- Key products like Quattro and Zenrelia are demonstrating strong performance and market share gains in major animal health markets.
3 days ago
Elanco Animal Health Discusses Growth, Innovation, and Debt Reduction
ELAN
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Elanco Animal Health has delivered nine consecutive quarters of growth and is focused on growth, innovation, and cash.
- The company has a basket of six approved innovations, with a seventh expected (IL-31), targeting major markets such as the $1.4 billion broad-spectrum parasiticide market (growing 40%) and the $2 billion dermatology market (growing double digits).
- Elanco is committed to reducing its debt from 3.7 times to the low threes/high twos, which is its number one use of cash, supported by EBITDA growth and the Elanco Ascend productivity initiative.
- Key products like Quattro are demonstrating strong market share gains, and Zenrelia is experiencing significant growth, particularly outside the U.S. where it is approved in 36 countries with a non-restrictive label.
- The company plans to provide further details on its trajectory for the rest of the decade and 2026 guidance at an upcoming investor day.
3 days ago
Elanco Animal Health Discusses Growth, Innovation, and Debt Reduction Strategy
ELAN
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Elanco Animal Health has delivered nine consecutive quarters of growth and is focused on a strategy of growth, innovation, and cash.
- The company is prioritizing debt reduction, having taken two turns of debt out in two years, and aims to reach low threes/high twos leverage soon, with a board commitment to reach the twos. This is the number one use of cash.
- Elanco's innovation basket includes six approved products, with a seventh (IL-31) expected, operating in major, fast-growing markets like the $1.4 billion oral broad-spectrum parasiticide market (growing 40%) and the $2 billion derm market (growing double digits).
- Management expects EBITDA growth next year, driven by blockbuster products and a new five-year Elanco Ascend productivity initiative focused on procurement, manufacturing, and gross-to-net.
- Further details on the 2026 outlook and the rest of the decade will be provided at an upcoming investor day.
3 days ago
Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ELAN
Earnings
Guidance Update
Product Launch
- Elanco reported strong Q3 2025 results, with 9% organic constant currency revenue growth, $1.137 billion in revenue, $198 million in adjusted EBITDA, and $0.19 in adjusted EPS.
- The company raised its full-year 2025 guidance, now expecting organic constant currency growth of 6%-6.5%, adjusted EBITDA of $880 million-$900 million, and adjusted EPS of $0.91-$0.94.
- Innovation revenue year-to-date reached $655 million, with full-year expectations raised to $840 million-$880 million; Credelio Quattro achieved blockbuster status with $100 million in net sales in less than eight months.
- The net leverage ratio improved to 3.7x at quarter-end, and Elanco refinanced its $2.1 billion term loan B facility, extending maturities through 2032.
Nov 5, 2025, 1:00 PM
Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ELAN
Earnings
Guidance Update
Product Launch
- Elanco reported strong Q3 2025 results, with 9% organic constant currency revenue growth to $1.137 billion, adjusted EBITDA of $198 million, and adjusted EPS of $0.19.
- The company raised its full-year 2025 guidance, now anticipating organic constant currency revenue growth of 6-6.5%, adjusted EBITDA of $880 million-$900 million, and adjusted EPS of $0.91-$0.94.
- Innovation revenue year-to-date reached $655 million, with the full-year expectation raised to $840 million-$880 million. Credelio Quattro achieved $100 million in net sales in less than eight months, and Experior grew 70% in Q3.
- Elanco improved its net leverage ratio to 3.7 times at quarter end and refinanced its $2.1 billion term loan B facility, extending maturities through 2032.
Nov 5, 2025, 1:00 PM
Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ELAN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Elanco reported strong Q3 2025 results, with 9% organic constant currency growth and $1.137 billion in revenue, exceeding guidance for revenue, adjusted EBITDA, and adjusted EPS.
- The company raised its full-year 2025 outlook, now projecting organic constant currency growth of 6-6.5%, adjusted EBITDA of $880-$900 million, and adjusted EPS of $0.91-$0.94.
- Full-year innovation revenue guidance was increased by $100 million at the midpoint to $840 million-$880 million, with Credelio Quattro reaching $100 million in net sales year-to-date through September.
- Elanco improved its net leverage ratio to 3.7 times at quarter end and refinanced its $2.1 billion term loan B facility, extending maturities through 2032.
- For 2026, the company expects margin expansion from the Elanco Ascend program and aims for a net leverage ratio under 3x longer term, despite an anticipated $15 million increase in interest expense.
Nov 5, 2025, 1:00 PM
Elanco Animal Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ELAN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Elanco Animal Health reported strong Q3 2025 results, with revenue of $1,137 million, Adjusted EBITDA of $198 million, and Adjusted Diluted EPS of $0.19, all exceeding guidance ranges. The company achieved 9% organic constant currency revenue growth.
- The company raised its full-year 2025 guidance, now expecting revenue between $4,645 million and $4,670 million, Adjusted EBITDA between $880 million and $900 million, and Adjusted Diluted EPS between $0.91 and $0.94.
- Year-to-date innovation revenue contribution reached $655 million, with the 2025 target raised to $840-$880 million.
- Elanco achieved a quarter-end net leverage ratio of 3.7x and improved its year-end target to 3.7x-3.8x, also successfully refinancing its 2027 Term Loan B.
Nov 5, 2025, 1:00 PM
Quarterly earnings call transcripts for Elanco Animal Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more